Targeting Myeloid Checkpoints For Brain Metastasis Treatment

Why This Research Matters
When cancer spreads to the brain—a process called brain metastasis—it becomes one of the most difficult stages of the disease to treat. For patients with aggressive cancers like melanoma or triple-negative breast cancer, these brain tumors are a leading cause of neurological issues and shortened life. While new treatments called immune checkpoint inhibitors (drugs that help the immune system recognize cancer) have been a breakthrough, they unfortunately only work for a small number of patients with brain tumors. There is an urgent need to understand why the brain environment helps cancer “hide” from the immune system.

What We Are Studying
Our research has uncovered a surprising clue: the brain’s own resident immune cells, called microglia, are being “reprogrammed” by the cancer to help the tumor grow instead of attacking it. We discovered that a specific protein called progranulin (PGRN) is a major culprit in this process. Interestingly, we found that the way the brain reacts to these tumors looks remarkably similar to the inflammation seen in Alzheimer’s disease. Our early studies show that when we remove this protein from the brain’s environment, the tumors have a much harder time growing. Most cancer research focuses solely on the cancer cells themselves.

How the Study Works
Our approach is highly innovative because it shifts the focus to the “soil”—the surrounding brain environment—and specifically targets the messages sent by the brain’s immune cells. We are using cutting-edge mapping technology to look at these cells in high resolution. Furthermore, because the brain is protected by a strict “border” called the blood-brain barrier, we are developing a “shuttle” system—specialized molecules designed to “hitch a ride” into the brain to deliver medicine where it is needed most.

Expected Impact
The goal of this project is to prove that blocking progranulin can “flip a switch” in the brain, turning an environment that protects cancer into one that actively fights it. We believe that by combining this new approach with existing immunotherapies, we can significantly enhance the body’s ability to destroy brain tumors. This research has the potential to redefine how we treat brain metastasis, offering hope and improved survival for patients who currently have very limited options. By addressing the unique challenges of the brain environment, we aim to turn a devastating diagnosis into a treatable condition.